AbbVie and Mylan agree Humira licensing deal
18-07-2018
AbbVie and Amgen settle Humira clash
29-09-2017
solidcolours / iStockphoto.com
AbbVie has announced that it has entered into a licensing deal with Germany-based pharmaceutical company Fresenius Kabi.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
licensing deal, biosimilars, patent licensing agreement, Humira, AbbVie, Fresenius Kabi, Michael Schönhofen
